medigraphic.com
ISSN 1995-9427 (Print)

2020, Number 3

<< Back Next >>

Invest Medicoquir 2020; 12 (3)

Usefulness of Ca 19-9 and CA-125 in the diagnosis of malignant bile duct stenosis

Barroso ML, Chao GL, Tusen TY, Samada SM, Moret VS, Rodríguez RH, Pérez GT

Language: Spanish
References: 20
Page:
PDF size: 389.39 Kb.


ABSTRACT

Introduction. Bile duct stenosis includes a broad spectrum of benign or malignant pancreatic hepatobiliary diseases; Sometimes it is complex to determine the benign or malignant aetiology of these lesions, which is why it is necessary to use effective and non-invasive methods such as smolecular biomarkers. Methods. A prospective diagnostic validation study was performed in 50 patients diagnosed with bile duct stenosis by endoscopic retrograde cholangiopancreatography (ERCP) in the period of one year, the main variables of the study were type of biliary stenosis, cytological study of biliary stenosis. and molecular biomarkers (CA-19.9; CA-125). Results. Male sex predominated in 60% of patients. The mean age was 64.7 years. 80% of the patients presented malignant-looking stenosis of the bile duct in ERCP and 20% benign-looking; more than 50% of the malignant stenosis presented high tumor markers and positive cytology. Conclusions. Tumor markers CA 19-9 and CA-125 are useful for the diagnosis of malignant bile duct strictures.


REFERENCES

  1. Moya-Sánchez.E y col. Claves para el diagnóstico diferencial de las estenosis biliares, cómo nos pueden ayudar las técnicas de imagen?.RAPD ON LINE. Noviembre 2017; 40(6).

  2. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010; 2(12):419‐27.

  3. Castrillón G y Gómez D. Obstrucción maligna de la vía biliar: hallazgos imagenológicosusuales y recientes. Rev. Colomb. Radiol. 2015;26(4):4317-27.

  4. Navaneethan U, Njei B, LourdusamyV,Konjeti R, Vargo J and ParsiM.Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. GastrointestEndosc. 2015. January; 81(1): 168–176.

  5. Hernán Z. y col. Experiencia con la colangiografía retrógrada endoscópica como procedimiento diagnóstico y terapeútico.Rev. Soc. Perú. Med.Interna.2006;19(2):37-46.

  6. Declaración de Helsinki

  7. Domper M, Simón M. Tratamiento endoscópico de la estenosis maligna de la vía biliar. Puesta al día y puntos más relevantes para la práctica clínica habitual. Rev EspEnferm Dig 2016;108(9):568-75.

  8. Koshitani T, Nakagawa S,Konaka Y, Nakano K, Fuki S,Itoh Y. Endoscopic deployment of multiple (≥ 3) metal stents for unresectable malignant hilar biliary strictures.Endoscopy International.2019; 07: 672–77.

  9. June S, Suk Y,GeunM,Hyub S, Shin† E, Hwang J. Triple-Tissue Sampling during Endoscopic RetrogradeCholangiopancreatography Increases the Overall Diagnostic Sensitivity for Cholangiocarcinoma. Gut and Liver. 2014 November;8(6): 669-73. Hyun L et al. Diagnosis of malignant biliary stricture: More is Better. Clinndosc. 2018 Mar; 51(2):115-17.

  10. Fairchild A y col. Appropriateness criteria radiologic management of biliary obstruction. Journal of the American College of Radiology.2019 May;16(5):196-213.

  11. Reza M et al. Diagnosis of malignant biliary strictures: Conventional or negative pressure brush cytology?.

  12. Kato M,et al. PeroralCholangioscopy-Guided Forceps Biopsy and Endoscopic Scraper for the Diagnosis ofIndeterminateExtrahepatic Biliary Stricture.J. Clin. Med. 2019; 8, 873; doi:10.3390/jcm8060873.

  13. Bowlus CL, Olson KA, Gershwin ME. Evaluation of indeterminate biliary strictures. Nat Rev GastroenterolHepatol.2016;13:28-37.

  14. Navaneethan U, Hasan M, Lourdusamy V, Njei B, Varadarajulu S, Hawes R. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review.GastrointestEndosc. 2015 October; 82(4): 608–14.

  15. Mino G, Naranjo A.Colangiocarcinomaextrahepático. Dificultades diagnósticas y opciones terapéuticas. Gastroenterología y Hepatología. 2000. 23(5):240-249.

  16. Medina G y col. Factores ictericia obstructiva benigna y maligna: utilidad del CA 19-9. Rev Gen 2016;70(2):54-60

  17. Tsen A et al. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology2018;18:862-867.

  18. JiY ,Joo T. Factors associated with malignant biliary strictures in patients with atypical or suspicious cells on brush cytology.Clin.Endosc. 2019;52:168-174

  19. Fang T,Wang H, Wang Y, Lin X. Clinical Significance of preoperative serum CEA, CA 125 and CA 19-9 levels in predicting the resectability of cholangiocarcinoma. Disease markers. 2019.

  20. Wang WSet al.Combined serum CA 19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer. Prev. Res. 2013;6(4):331-8.




2020     |     www.medigraphic.com